Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Spine (Phila Pa 1976). 2016 Jan;41(2):173–181. doi: 10.1097/BRS.0000000000001180

Table 3.

Specific patient comorbidities

Comorbidity TDA Fusion P-value^

Counts Percentage (%) Counts Percentage (%)

Arrhythmias 67 2.77 1543 3.06 0.4669
Arthritis* 10 0.41 863 1.71 <0.0001
Atherosclerosis* 23 0.95 1306 2.59 <0.0001
Cancer* 5 0.21 440 0.87 <0.0001
Cellulitis 6 0.25 190 0.38 0.3917
CHF* 3 0.12 365 0.72 <0.0001
COPD* 37 1.53 1716 3.40 <0.0001
Decubitus* 0 0.00 162 0.32 0.001
Dementia* 9 0.37 464 0.92 0.0027
Diabetes mellitus* 92 3.81 4724 9.36 <0.0001
ESRD 0 0.00 51 0.10 0.1745
Hematological 0 0.00 48 0.10 0.1729
Hemiplegia* 3 0.12 1363 2.70 <0.0001
Hypertension* 383 15.86 14078 27.90 <0.0001
Infection* 26 1.08 1151 2.28 <0.0001
Major symptoms 132 5.47 3013 5.97 0.3325
Metastatic* 0 0.00 265 0.53 <0.0001
Neuropathy* 12 0.50 608 1.20 0.0007
Other injury 90 3.73 1604 3.18 0.1389
Pneumonia 4 0.17 205 0.41 0.0668
Protein 5 0.21 168 0.33 0.3629
Psychiatric* 33 1.37 1395 2.76 <0.0001
Renal* 6 0.25 585 1.16 <0.0001
Stroke 0 0.00 29 0.06 0.6422
Vascular* 58 2.40 1918 3.80 0.0002

Percentage (%) reflects the frequency of that comorbidity in all patients undergoing that procedure.

^

Significant differences determined based on Fisher’s exact tests (P<0.05).

*

Comorbidities with significant differences between groups.